000079821 001__ 79821
000079821 005__ 20230914083233.0
000079821 0247_ $$2doi$$a10.1186/s40545-019-0181-2
000079821 0248_ $$2sideral$$a112646
000079821 037__ $$aART-2019-112646
000079821 041__ $$aeng
000079821 100__ $$0(orcid)0000-0001-9962-3387$$aFrutos Pérez-Surio, Alberto$$uUniversidad de Zaragoza
000079821 245__ $$aSystematic review for the development of a pharmaceutical and medical products prioritization framework
000079821 260__ $$c2019
000079821 5060_ $$aAccess copy available to the general public$$fUnrestricted
000079821 5203_ $$aObjective
To identify and analyze the criteria, approaches, and conceptual frameworks, used for national/international priority setting.
Data sources
We performed a search of the main biomedical databases (Medline/PubMed, Embase, Centre for Reviews and Dissemination, and Cochrane), and we reviewed assessment agency websites, among other sources.
Study design
An systematic review of the literature was carried out.
Data collection
Eligibility criteria for inclusion were based on set of predefined criteria. Systematic reviews and/or qualitative studies (interviews, surveys, expert consensus, etc) that aimed to identify prioritization criteria or develop general operational frameworks for the selection of health priorities were included. A critical analysis is made of all the aspects that may be useful for any public body that intends to establish priorities in health.
Principal findings
We found that there are no standardized criteria for priority setting, although common trends have been identified regarding key elements. Eight key domains were identified: 1) need for intervention; 2) health outcomes; 3) type of benefit of the intervention; 4) economic consequences; 5) existing knowledge on the intervention/quality and uncertainties of the regarding evidence; 6) implementation and complexity of the intervention/feasibility; 7) justice and ethics; and 8) overall context.
Conclusions
Our review provides a thorough analysis of the relevant issues and offers key recommendations regarding considerations for developing a national prioritization framework. Findings are envisioned to be useful for different public organizations that are aiming to establish healthcare priorities.
000079821 540__ $$9info:eu-repo/semantics/openAccess$$aby$$uhttp://creativecommons.org/licenses/by/3.0/es/
000079821 592__ $$a0.644$$b2019
000079821 593__ $$aPharmacology, Toxicology and Pharmaceutics (miscellaneous)$$c2019$$dQ1
000079821 593__ $$aHealth Policy$$c2019$$dQ2
000079821 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000079821 700__ $$aGimeno-Gracia, Mercedes
000079821 700__ $$aAlcácera López, María Aránzazu
000079821 700__ $$aSagredo Samanes, María Asunción
000079821 700__ $$aPardo Jario, María del Puerto
000079821 700__ $$aSalvador Gómez, María del Tránsito
000079821 7102_ $$11008$$2615$$aUniversidad de Zaragoza$$bDpto. Microb.Med.Pr.,Sal.Públ.$$cÁrea Medic.Prevent.Salud Públ.
000079821 773__ $$g12, 21 (2019), 1-7$$tJournal of Pharmaceutical Policy and Practice$$x2052-3211
000079821 8564_ $$s853898$$uhttps://zaguan.unizar.es/record/79821/files/texto_completo.pdf$$yVersión publicada
000079821 8564_ $$s101041$$uhttps://zaguan.unizar.es/record/79821/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000079821 909CO $$ooai:zaguan.unizar.es:79821$$particulos$$pdriver
000079821 951__ $$a2023-09-13-10:44:57
000079821 980__ $$aARTICLE